Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0 0
Stock impact report

IBEX Limited: A Hidden Growth Engine In Healthtech [Seeking Alpha]

IBEX Limited - Common Share (IBEX) 
Company Research Source: Seeking Alpha
HealthTech segment grew 35% YoY, now 17.4% of revenue, with management targeting $100M by year-end, signaling a strategic shift to high-profit sectors. Q2 2026 revenues rose 16.7% YoY to $164.2M, with adjusted EBITDA margin improving to 12.6% due to cost efficiencies and segment mix. I assign IBEX a buy rating, citing strong execution, robust guidance, and catalysts from HealthTech expansion, but advise monitoring HealthTech growth and client concentration risks. Funtap/iStock via Getty Images IBEX Limited ( IBEX ) traditionally operated as a service contractor or business process outsourcing, but recently the company decided to expand into the HealthTech sector to manage the revenue cycle for medical entities, which could Show less Read more
Impact Snapshot
Event Time:
IBEX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
IBEX alerts

from News Quantified
Opt-in for
IBEX alerts

from News Quantified